European Journal of Nuclear Medicine and Molecular Imaging

, Volume 37, Issue 3, pp 594–605

[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging


  • Laëtitia Lemoine
    • Laboratory of NeuropharmacologyUniversité de Lyon
    • PET DepartmentCERMEP – Imagerie du Vivant
  • Mathieu Verdurand
    • Laboratory of NeuropharmacologyUniversité de Lyon
    • PET DepartmentCERMEP – Imagerie du Vivant
  • Bernard Vacher
    • Centre de Recherches Pierre Fabre
  • Elodie Blanc
    • Centre de Recherches Pierre Fabre
  • Didier Le Bars
    • PET DepartmentCERMEP – Imagerie du Vivant
  • Adrian Newman-Tancredi
    • Centre de Recherches Pierre Fabre
    • Laboratory of NeuropharmacologyUniversité de Lyon
    • PET DepartmentCERMEP – Imagerie du Vivant
    • ANIMAGE DepartmentCERMEP – Imagerie du Vivant
Original Article

DOI: 10.1007/s00259-009-1274-y

Cite this article as:
Lemoine, L., Verdurand, M., Vacher, B. et al. Eur J Nucl Med Mol Imaging (2010) 37: 594. doi:10.1007/s00259-009-1274-y



The serotonin-1A (5-HT1A) receptor is implicated in the pathophysiology of major neuropsychiatric disorders. Thus, the functional imaging of 5-HT1A receptors by positron emission tomography (PET) may contribute to the understanding of its role in those pathologies and their therapeutics. These receptors exist in high- and low-affinity states and it is proposed that agonists bind preferentially to the high-affinity state of the receptor and therefore could provide a measure of the functional 5-HT1A receptors. Since all clinical PET 5-HT1A radiopharmaceuticals are antagonists, it is of great interest to develop a 18F labelled agonist.


F15599 (3-chloro-4-fluorophenyl-(4-fluoro-4{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone) is a novel ligand with high affinity and selectivity for 5-HT1A receptors and is currently tested as an antidepressant. In pharmacological tests in rat, it exhibits preferential agonist activity at post-synaptic 5-HT1A receptors in cortical brain regions. Here, its nitro-precursor was synthesised and radiolabelled via a fluoronucleophilic substitution. Radiopharmacological evaluations included in vitro and ex vivo autoradiography in rat brain and PET scans on rats and cats. Results were compared with simultaneous studies using [18F]MPPF, a validated 5-HT1A antagonist radiopharmaceutical.


The chemical and radiochemical purities of [18F]F15599 were >98%. In vitro [18F]F15599 binding was consistent with the known 5-HT1A receptors distribution (hippocampus, dorsal raphe nucleus, and notably cortical areas) and addition of Gpp(NH)p inhibited [18F]F15599 binding, consistent with a specific binding to G protein-coupled receptors. In vitro binding of [18F]F15599 was blocked by WAY100635 and 8-OH-DPAT, respectively, prototypical 5-HT1A antagonist and agonist. The ex vivo and in vivo studies demonstrated that the radiotracer readily entered the rat and the cat brain and generated few brain radioactive metabolites. Remarkably, in microPET studies, [18F]F15599 notably displayed a pattern of brain labelling that did not correlate with in vitro observations. Thus, in cat, the highest binding was observed in dorsal raphe and cingulate cortex with little binding in other cortical regions and none in hippocampus. In vivo binding was abolished by WAY100635, indicating specific labelling of 5-HT1A receptors.


[18F]F15599 is a radiofluorinated agonist presenting interesting characteristics for probing in vitro and in vivo the high-affinity states of the 5-HT1A receptors. Its differential labelling of 5-HT1A receptors in vitro and in vivo may result from its reported preferential interaction with receptors coupled to specific G-protein subtypes.


Serotonin 1A receptorPETAgonistRatCat

Copyright information

© Springer-Verlag 2009